144 related articles for article (PubMed ID: 31959348)
1. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
[TBL] [Abstract][Full Text] [Related]
2. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
3. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
[TBL] [Abstract][Full Text] [Related]
4. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
[TBL] [Abstract][Full Text] [Related]
6. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
Agrawal S; Feng Y; Roy A; Kollia G; Lestini B
J Immunother Cancer; 2016; 4():72. PubMed ID: 27879974
[TBL] [Abstract][Full Text] [Related]
8. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
J Oncol Pharm Pract; 2023 Sep; ():10781552231199048. PubMed ID: 37654194
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
10. Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Samlowski W; Robert NJ; Chen L; Schenkel B; Davis C; Moshyk A; Kotapati S; Poretta T; Weber JS
Cancer Med; 2023 Feb; 12(3):2378-2388. PubMed ID: 35880244
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
Langley RG; Papp K; Gooderham M; Zhang L; Mallinckrodt C; Agada N; Blauvelt A; Foley P; Polzer P;
Br J Dermatol; 2018 Jun; 178(6):1315-1323. PubMed ID: 29405255
[TBL] [Abstract][Full Text] [Related]
12. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
Papp K; Maari C; Cauthen A; Gooderham M; Spelman L; Yamanaka K; Polzer P; Zhang L; Osuntokun O; Augustin M
Br J Dermatol; 2020 Jul; 183(1):52-59. PubMed ID: 31545506
[TBL] [Abstract][Full Text] [Related]
13. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
[TBL] [Abstract][Full Text] [Related]
14. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
Sheng J; Zhang J; Baudelet C; Roy A
J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
[TBL] [Abstract][Full Text] [Related]
15. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J; Cai J; Bello A; Roy A; Sheng J
J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
[TBL] [Abstract][Full Text] [Related]
16. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
17. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
20. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
